Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
NCT ID: NCT02873195
Last Updated: 2024-08-23
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
133 participants
Study Classification
INTERVENTIONAL
Study Start Date
2017-07-07
Study Completion Date
2023-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This randomized phase II trial studies how well capecitabine and bevacizumab with or without atezolizumab work in treating patients with colorectal cancer that is not responding to treatment and has spread to other places. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body?s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab with capecitabine and bevacizumab may be a better way in treating colorectal cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Bevacizumab Plus Capecitabine (Xeloda) in Patients With Untreated Metastatic Colorectal Cancer
NCT00203411
Colorectal Cancer
COMPLETED
PHASE2
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
NCT00107315
Colorectal Cancer
TERMINATED
PHASE2
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT00467142
Colorectal Cancer
COMPLETED
PHASE2
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
NCT00025337
Adenocarcinoma of the Colon
Adenocarcinoma of the Rectum
Recurrent Colon Cancer
+5 more
COMPLETED
PHASE3
Combination Chemotherapy and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00628810
Colorectal Cancer
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
PRIMARY OBJECTIVE:
I. To estimate the efficacy of capecitabine/bevacizumab + atezolizumab, as compared with capecitabine/bevacizumab + placebo in refractory metastatic colorectal cancer (mCRC) as measured by progression-free survival (defined as the time of randomization to the first occurrence of progression based on Response Evaluation Criteria in Solid Tumors version 1.1, clinical progression, or death from any cause on study as determined by the investigator).
SECONDARY OBJECTIVES:
I. To estimate the efficacy of capecitabine/bevacizumab + atezolizumab, as compared with capecitabine/bevacizumab + placebo in refractory mCRC as measured by objective response rate (defined as partial response plus complete response) as determined by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 and immune-related response criteria (irRC).
II. To estimate the efficacy of capecitabine/bevacizumab + atezolizumab as compared with capecitabine/bevacizumab + placebo in refractory mCRC as measured by overall survival (defined as death from any cause from the time of randomization until study completion).
III. To evaluate the safety and tolerability of atezolizumab in combination with bevacizumab and capecitabine in refractory mCRC as measured by the serious adverse events and adverse events \>= grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
CORRELATIVE OBJECTIVE:
I. To explore any correlation between tissue and blood based biomarkers and clinical outcomes.
OUTLINE: Patients are randomized 2:1 to Arm I:Arm II.
ARM I (ATEZOLIZUMAB, BEVACIZUMAB, CAPECITABINE): Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine orally (PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II (PLACEBO, BEVACIZUMAB, CAPECITABINE): Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, every 3 months until progressive disease, then every 6 months thereafter.
I. To estimate the efficacy of capecitabine/bevacizumab + atezolizumab, as compared with capecitabine/bevacizumab + placebo in refractory metastatic colorectal cancer (mCRC) as measured by progression-free survival (defined as the time of randomization to the first occurrence of progression based on Response Evaluation Criteria in Solid Tumors version 1.1, clinical progression, or death from any cause on study as determined by the investigator).
SECONDARY OBJECTIVES:
I. To estimate the efficacy of capecitabine/bevacizumab + atezolizumab, as compared with capecitabine/bevacizumab + placebo in refractory mCRC as measured by objective response rate (defined as partial response plus complete response) as determined by the investigator using Response Evaluation Criteria in Solid Tumors version 1.1 and immune-related response criteria (irRC).
II. To estimate the efficacy of capecitabine/bevacizumab + atezolizumab as compared with capecitabine/bevacizumab + placebo in refractory mCRC as measured by overall survival (defined as death from any cause from the time of randomization until study completion).
III. To evaluate the safety and tolerability of atezolizumab in combination with bevacizumab and capecitabine in refractory mCRC as measured by the serious adverse events and adverse events \>= grade 3 according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
CORRELATIVE OBJECTIVE:
I. To explore any correlation between tissue and blood based biomarkers and clinical outcomes.
OUTLINE: Patients are randomized 2:1 to Arm I:Arm II.
ARM I (ATEZOLIZUMAB, BEVACIZUMAB, CAPECITABINE): Patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine orally (PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
ARM II (PLACEBO, BEVACIZUMAB, CAPECITABINE): Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 30 days, every 3 months until progressive disease, then every 6 months thereafter.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Metastatic Colorectal Carcinoma
Recurrent Colorectal Carcinoma
Refractory Colorectal Carcinoma
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
TREATMENT
Blinding Strategy
DOUBLE
Participants
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm I (atezolizumab, bevacizumab, capecitabine)
Patients receive atezolizumab IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group Type
EXPERIMENTAL
Atezolizumab
Intervention Type
DRUG
Given IV
Bevacizumab
Intervention Type
BIOLOGICAL
Given IV
Capecitabine
Intervention Type
DRUG
Given PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Arm II (placebo, bevacizumab, capecitabine)
Patients receive placebo IV over 30-60 minutes on day 1, bevacizumab IV over 30-90 minutes on day 1, and capecitabine PO BID on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Group Type
ACTIVE_COMPARATOR
Bevacizumab
Intervention Type
BIOLOGICAL
Given IV
Capecitabine
Intervention Type
DRUG
Given PO
Laboratory Biomarker Analysis
Intervention Type
OTHER
Correlative studies
Placebo
Intervention Type
OTHER
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atezolizumab
Given IV
Intervention Type
DRUG
Bevacizumab
Given IV
Intervention Type
BIOLOGICAL
Capecitabine
Given PO
Intervention Type
DRUG
Laboratory Biomarker Analysis
Correlative studies
Intervention Type
OTHER
Placebo
Given IV
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
MPDL 3280A
MPDL 328OA
MPDL-3280A
MPDL3280A
MPDL328OA
RG7446
RO5541267
Tecentriq
Anti-VEGF
Anti-VEGF Humanized Monoclonal Antibody
Anti-VEGF rhuMAb
Avastin
Bevacizumab awwb
Bevacizumab Biosimilar BEVZ92
Bevacizumab Biosimilar BI 695502
Bevacizumab Biosimilar CBT 124
Bevacizumab Biosimilar CT-P16
Bevacizumab Biosimilar FKB238
Bevacizumab Biosimilar HD204
Bevacizumab Biosimilar HLX04
Bevacizumab Biosimilar IBI305
Bevacizumab Biosimilar LY01008
Bevacizumab Biosimilar MIL60
Bevacizumab Biosimilar QL 1101
Bevacizumab Biosimilar RPH-001
Bevacizumab Biosimilar SCT501
BP102
BP102 Biosimilar
HD204
Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer
Recombinant Humanized Anti-VEGF Monoclonal Antibody
rhuMab-VEGF
SCT501
Ro 09-1978/000
Xeloda
placebo therapy
PLCB
sham therapy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed colorectal cancer that is either clinically or histologically proven to be metastatic and has progressed on regimens containing a fluoropyrimidine (e.g., 5-fluorouracil or capecitabine), oxaliplatin, irinotecan, bevacizumab and an anti-EGFR antibody (if tumor is RAS wild-type), or where the treatment was not tolerated or contraindicated
* Measurable disease; Note: previously irradiated sites can be included if there is documented disease progression in that site
* Capecitabine and bevacizumab considered appropriate treatment for the patient
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* Absolute neutrophil count \>= 1,500/uL (obtained =\< 7 days prior to randomization)
* Platelets \>= 100,000/uL (obtained =\< 7 days prior to randomization)
* Total bilirubin =\< 1.5 X upper limit of normal (ULN) (obtained =\< 7 days prior to randomization); patients with known Gilbert?s syndrome who have serum bilirubin =\< 3 X ULN may enroll
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 1.5 X ULN; \< 3 X ULN if known hepatic metastases (obtained =\< 7 days prior to randomization)
* Hemoglobin \>= 9 g/dL continuation of erythropoietin products is permitted (obtained =\< 7 days prior to randomization); hemoglobin must be stable \>= 9 g/dL \>= 14 days without blood transfusion to maintain hemoglobin level
* Calculated creatinine clearance must be \>= 50 ml/min using the Cockcroft-Gault formula or a 24 hour urine (obtained =\< 7 days prior to randomization)
* The following laboratory values obtained =\< 14 days prior to randomization
* Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =\< 1.5 X ULN if not anticoagulated; within local institutional guidelines per local physician if anticoagulated
* Negative pregnancy test done =\< 7 days prior to randomization, for women of childbearing potential only
* Provide informed written consent
* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Willingness to provide tissue and blood samples for correlative research purposes
* Life expectancy of \>= 3 months
* Measurable disease; Note: previously irradiated sites can be included if there is documented disease progression in that site
* Capecitabine and bevacizumab considered appropriate treatment for the patient
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
* Absolute neutrophil count \>= 1,500/uL (obtained =\< 7 days prior to randomization)
* Platelets \>= 100,000/uL (obtained =\< 7 days prior to randomization)
* Total bilirubin =\< 1.5 X upper limit of normal (ULN) (obtained =\< 7 days prior to randomization); patients with known Gilbert?s syndrome who have serum bilirubin =\< 3 X ULN may enroll
* Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =\< 1.5 X ULN; \< 3 X ULN if known hepatic metastases (obtained =\< 7 days prior to randomization)
* Hemoglobin \>= 9 g/dL continuation of erythropoietin products is permitted (obtained =\< 7 days prior to randomization); hemoglobin must be stable \>= 9 g/dL \>= 14 days without blood transfusion to maintain hemoglobin level
* Calculated creatinine clearance must be \>= 50 ml/min using the Cockcroft-Gault formula or a 24 hour urine (obtained =\< 7 days prior to randomization)
* The following laboratory values obtained =\< 14 days prior to randomization
* Prothrombin time (PT)/partial thromboplastin time (PTT)/international normalized ratio (INR) =\< 1.5 X ULN if not anticoagulated; within local institutional guidelines per local physician if anticoagulated
* Negative pregnancy test done =\< 7 days prior to randomization, for women of childbearing potential only
* Provide informed written consent
* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)
* Willingness to provide tissue and blood samples for correlative research purposes
* Life expectancy of \>= 3 months
Exclusion Criteria
* Any of the following:
* Pregnant women
* Nursing women
* Women of child-bearing potential must agree to use two forms of adequate contraception from time of initial consent, for the duration of study participation, and for \>= 6 months after the last dose of study drug; medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); contraceptive measures such as Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use; postmenopausal woman must have been amenorrheic for at least 2 years to be considered of non-childbearing potential; sexually active men must use at least one form of adequate contraception from time of initial consent, for the duration of study participation, and for \>= 6 months after the last dose of study drug
* Chemotherapy, biologic anti-cancer therapy, or central field radiation therapy =\< 28 days prior to randomization; Note: local or stereotactic radiation =\< 14 days prior to randomization
* Any investigational agent =\< 28 days or 5 half-lives prior to randomization (whichever is longer)
* Prior treatment with atezolizumab or another PD-L1/PD-1 therapy
* History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager
* Known untreated central nervous system (CNS) metastases; Note: patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for this purpose =\< 30 days prior to randomization
* Inadequately controlled hypertension (defined as average systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg)
* History of hypertensive crisis or hypertensive encephalopathy
* New York Heart Association (NYHA) grade II or greater congestive heart failure
* History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery =\< 12 months prior to randomization
* Active coronary heart disease evidenced as angina or requiring medications to prevent angina
* History of stroke or transient ischemic attack, or other arterial thrombosis =\< 12 months prior to randomization
* Symptomatic peripheral vascular disease
* Any other significant vascular disease (e.g., aortic aneurysm, aortic dissection, or carotid stenosis that requires medical or surgical intervention, including angioplasty or stenting)
* Any previous National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 4 venous thromboembolism
* Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician
* History of active gastrointestinal (GI) bleeding or other major bleeding =\< 12 months prior to randomization; Note: patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded
* Major surgical procedure, open biopsy, or significant traumatic injury =\< 56 days prior to randomization
* Anticipation of need for major surgical procedure =\< 6 months after randomization
* Minor surgical procedure =\< 7 days prior to randomization; exception: insertion of an indwelling catheter or percutaneous needle biopsy =\< 48 hours prior to randomization
* History of intra-abdominal abscess =\< 6 months prior to randomization; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll
* History of abdominal or other significant fistula, gastrointestinal or other organ perforation; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll
* Serious, non-healing wound, ulcer, or bone fracture as so judged by the treating physician
* Known proteinuria defined by \>= 2+ protein by urinalysis (UA) or \>= 1 gram protein by 24 hour urine collection; Note: Subjects that are \>= 2+ or greater on dipstick but \< 1 g protein on 24 hour urine ARE eligible to participate
* Intolerance to bevacizumab defined as any NCI CTCAE grade 3 or grade 4 toxicity attributed to this agent that required discontinuation of bevacizumab (e.g., arterial thromboembolism \[ATE\], perforation, wound healing difficulty, proteinuria, reversible posterior leukoencephalopathy syndrome \[RPLS\]); Note: patients with prior grade 3 bevacizumab-related hypertension may be permitted if hypertension was manageable with standard oral antihypertensives as so judged by the treating physician
* Known dihydropyrimidine dehydrogenase (DPD) deficiency
* Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption
* Active inflammatory bowel disease
* History of diverticulitis, chronic ulcerative lower GI disease such as Crohn?s disease or ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforations
* History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener?s granulomatosis, Sjogren?s syndrome, Bell?s palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; Note: patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study
* Active current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, herpes zoster, and human immunodeficiency virus (HIV), but excluding fungal infections of nail beds
* Vaccination with a live or attenuated vaccine =\< 28 days prior to randomization; Note: other types of vaccines, including inactivated/killed, toxoid (inactivated toxoid), and subunit/conjugate are all permitted at any time
* Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =\< 1 except neuropathy
* Other concurrent severe and/or uncontrolled medical disease, psychiatric illness, or social situation, which could compromise safety of treatment as so judged by the treating physician; Note: this includes but is not limited to: severely impaired lung function, uncontrolled diabetes (history of consistent blood glucose readings above 300 mg/dL or less than 50 mg/dL), severe infection, severe malnutrition, ventricular arrhythmias, known active vasculitis of any cause, tumor invasion of any major blood vessel, chronic liver or renal disease, and active upper GI tract ulceration
* Unwilling to or unable to comply with the protocol
* Current or recent (=\< 10 days prior to randomization) use of aspirin (\> 325 mg/day), or clopidogrel (\> 75 mg/day)
* Current or recent (=\< 10 days prior to randomization) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes, unless the patient has been on a stable dose of anticoagulants for at least 2 weeks at the time of randomization; Note: the use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants \>= 14 days at the time of randomization; prophylactic use of anticoagulants is allowed
* History or recent diagnosis of demyelinating disease
* History of other carcinoma =\< 3 years; exception: if risk of recurrence is known to be under 5% at time of randomization
* Current or recent (=\< 90 days prior to randomization) endoluminal stent in the stomach, bowel, colon or rectum
* Colonoscopy, sigmoidoscopy, or proctoscopy =\< 7 days prior to randomization
* Current or recent (=\< 28 days prior to randomization) use of sorivudine, brivudine, and St. John?s wort
* Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation
* Prior allogeneic bone marrow transplantation or prior solid organ transplantation
* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] agents) =\< 14 days prior to randomization; exception: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) are eligible; the use of inhaled corticosteroids and mineral-corticoids (e.g. fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
* Pregnant women
* Nursing women
* Women of child-bearing potential must agree to use two forms of adequate contraception from time of initial consent, for the duration of study participation, and for \>= 6 months after the last dose of study drug; medically acceptable contraceptives include: (1) surgical sterilization (such as a tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD); contraceptive measures such as Plan B, sold for emergency use after unprotected sex, are not acceptable methods for routine use; postmenopausal woman must have been amenorrheic for at least 2 years to be considered of non-childbearing potential; sexually active men must use at least one form of adequate contraception from time of initial consent, for the duration of study participation, and for \>= 6 months after the last dose of study drug
* Chemotherapy, biologic anti-cancer therapy, or central field radiation therapy =\< 28 days prior to randomization; Note: local or stereotactic radiation =\< 14 days prior to randomization
* Any investigational agent =\< 28 days or 5 half-lives prior to randomization (whichever is longer)
* Prior treatment with atezolizumab or another PD-L1/PD-1 therapy
* History of allergic reactions attributed to therapeutic antibodies; Note: patients with reactions to chimeric antibodies may be permitted on a case by case basis with approval by study chair by contacting the data manager
* Known untreated central nervous system (CNS) metastases; Note: patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no steroids have been administered for this purpose =\< 30 days prior to randomization
* Inadequately controlled hypertension (defined as average systolic blood pressure \> 150 mmHg and/or diastolic blood pressure \> 100 mmHg)
* History of hypertensive crisis or hypertensive encephalopathy
* New York Heart Association (NYHA) grade II or greater congestive heart failure
* History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery =\< 12 months prior to randomization
* Active coronary heart disease evidenced as angina or requiring medications to prevent angina
* History of stroke or transient ischemic attack, or other arterial thrombosis =\< 12 months prior to randomization
* Symptomatic peripheral vascular disease
* Any other significant vascular disease (e.g., aortic aneurysm, aortic dissection, or carotid stenosis that requires medical or surgical intervention, including angioplasty or stenting)
* Any previous National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade 4 venous thromboembolism
* Clinically-significant evidence of bleeding diathesis or coagulopathy as so judged by the treating physician
* History of active gastrointestinal (GI) bleeding or other major bleeding =\< 12 months prior to randomization; Note: patients who do not have resolution of the predisposing risk factor (e.g., resection of a bleeding tumor, treatment and endoscopic documentation of a resolved ulcer) will also be excluded
* Major surgical procedure, open biopsy, or significant traumatic injury =\< 56 days prior to randomization
* Anticipation of need for major surgical procedure =\< 6 months after randomization
* Minor surgical procedure =\< 7 days prior to randomization; exception: insertion of an indwelling catheter or percutaneous needle biopsy =\< 48 hours prior to randomization
* History of intra-abdominal abscess =\< 6 months prior to randomization; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll
* History of abdominal or other significant fistula, gastrointestinal or other organ perforation; Note: if the affected area was surgically resected, and there is no further risk to the area, patients may enroll
* Serious, non-healing wound, ulcer, or bone fracture as so judged by the treating physician
* Known proteinuria defined by \>= 2+ protein by urinalysis (UA) or \>= 1 gram protein by 24 hour urine collection; Note: Subjects that are \>= 2+ or greater on dipstick but \< 1 g protein on 24 hour urine ARE eligible to participate
* Intolerance to bevacizumab defined as any NCI CTCAE grade 3 or grade 4 toxicity attributed to this agent that required discontinuation of bevacizumab (e.g., arterial thromboembolism \[ATE\], perforation, wound healing difficulty, proteinuria, reversible posterior leukoencephalopathy syndrome \[RPLS\]); Note: patients with prior grade 3 bevacizumab-related hypertension may be permitted if hypertension was manageable with standard oral antihypertensives as so judged by the treating physician
* Known dihydropyrimidine dehydrogenase (DPD) deficiency
* Impairment of GI function or GI disease that may significantly alter capecitabine drug absorption
* Active inflammatory bowel disease
* History of diverticulitis, chronic ulcerative lower GI disease such as Crohn?s disease or ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforations
* History of autoimmune disease including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener?s granulomatosis, Sjogren?s syndrome, Bell?s palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; Note: patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for this study
* Active current infection or history of recurrent bacterial, viral, fungal, mycobacterial or other infections, including but not limited to tuberculosis and atypical mycobacterial disease, hepatitis B and C, herpes zoster, and human immunodeficiency virus (HIV), but excluding fungal infections of nail beds
* Vaccination with a live or attenuated vaccine =\< 28 days prior to randomization; Note: other types of vaccines, including inactivated/killed, toxoid (inactivated toxoid), and subunit/conjugate are all permitted at any time
* Any reversible treatment-related toxicity that has not resolved to NCI CTCAE grade =\< 1 except neuropathy
* Other concurrent severe and/or uncontrolled medical disease, psychiatric illness, or social situation, which could compromise safety of treatment as so judged by the treating physician; Note: this includes but is not limited to: severely impaired lung function, uncontrolled diabetes (history of consistent blood glucose readings above 300 mg/dL or less than 50 mg/dL), severe infection, severe malnutrition, ventricular arrhythmias, known active vasculitis of any cause, tumor invasion of any major blood vessel, chronic liver or renal disease, and active upper GI tract ulceration
* Unwilling to or unable to comply with the protocol
* Current or recent (=\< 10 days prior to randomization) use of aspirin (\> 325 mg/day), or clopidogrel (\> 75 mg/day)
* Current or recent (=\< 10 days prior to randomization) use of therapeutic oral or parenteral anticoagulants or thrombolytic agents for therapeutic purposes, unless the patient has been on a stable dose of anticoagulants for at least 2 weeks at the time of randomization; Note: the use of full-dose oral or parenteral anticoagulants is permitted as long as the INR or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the institution) and the patient has been on a stable dose of anticoagulants \>= 14 days at the time of randomization; prophylactic use of anticoagulants is allowed
* History or recent diagnosis of demyelinating disease
* History of other carcinoma =\< 3 years; exception: if risk of recurrence is known to be under 5% at time of randomization
* Current or recent (=\< 90 days prior to randomization) endoluminal stent in the stomach, bowel, colon or rectum
* Colonoscopy, sigmoidoscopy, or proctoscopy =\< 7 days prior to randomization
* Current or recent (=\< 28 days prior to randomization) use of sorivudine, brivudine, and St. John?s wort
* Primary or secondary immunodeficiency (history of or currently active) unless related to primary disease under investigation
* Prior allogeneic bone marrow transplantation or prior solid organ transplantation
* Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-TNF\] agents) =\< 14 days prior to randomization; exception: patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time dose of dexamethasone for nausea) are eligible; the use of inhaled corticosteroids and mineral-corticoids (e.g. fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
collaborator
Academic and Community Cancer Research United
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Niharika Mettu
Role: PRINCIPAL_INVESTIGATOR
Academic and Community Cancer Research United
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic Hospital
Phoenix, Arizona, United States
Site Status
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Site Status
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Site Status
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Site Status
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States
Site Status
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site Status
Mayo Clinic
Rochester, Minnesota, United States
Site Status
Roswell Park Cancer Institute
Buffalo, New York, United States
Site Status
Duke University Medical Center
Durham, North Carolina, United States
Site Status
Rhode Island Hospital
Providence, Rhode Island, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Mettu NB, Ou FS, Zemla TJ, Halfdanarson TR, Lenz HJ, Breakstone RA, Boland PM, Crysler OV, Wu C, Nixon AB, Bolch E, Niedzwiecki D, Elsing A, Hurwitz HI, Fakih MG, Bekaii-Saab T. Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open. 2022 Feb 1;5(2):e2149040. doi: 10.1001/jamanetworkopen.2021.49040.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2016-01263
Identifier Type: REGISTRY
Identifier Source: secondary_id
RU021416I
Identifier Type: OTHER
Identifier Source: secondary_id
RU021416I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
NCT00826540
COMPLETED
PHASE2
Second-Line Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer Who Have Received First-Line Chemotherapy and Bevacizumab
NCT00720512
TERMINATED
PHASE3
caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.
NCT06171854
ACTIVE_NOT_RECRUITING
PHASE2
Study With AG-013736 Combined With Chemotherapy And Bevacizumab In Patients With Metastatic Colorectal Cancer
NCT00460603
COMPLETED
PHASE1/PHASE2
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00544011
UNKNOWN
PHASE2
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
NCT02982694
TERMINATED
PHASE2
Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer
NCT01722162
COMPLETED
PHASE2
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
NCT00290615
COMPLETED
PHASE2
Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20)
NCT01900717
COMPLETED
PHASE2
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
NCT01506167
COMPLETED
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00098787
COMPLETED
PHASE2
A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer
NCT00623805
COMPLETED
PHASE3
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
NCT07284849
NOT_YET_RECRUITING
PHASE3
Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer
NCT00027833
UNKNOWN
PHASE2
A Study Combining mFOLFOX6 With Tivozanib or Bevacizumab in Patients With Metastatic Colorectal Cancer as First Line Therapy
NCT01478594
COMPLETED
PHASE2
Cetuximab and Bevacizumab as First-Line Therapy Followed By Combination Chemotherapy and Bevacizumab With or Without Cetuximab as Second-Line Therapy in Treating Patients With Stage IV Colorectal Cancer
NCT00571740
WITHDRAWN
PHASE2
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
NCT00077298
COMPLETED
PHASE2
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
NCT00700102
COMPLETED
PHASE3
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
NCT02743221
COMPLETED
PHASE2
Capecitabine Plus Oxaliplatin Plus Bevacizumab as First-line Treatment in Elderly Patients With Metastatic Colorectal Cancer
NCT01024504
COMPLETED
PHASE2
Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
NCT07085169
RECRUITING
PHASE2
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
NCT00321100
TERMINATED
PHASE2
Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
NCT00544700
TERMINATED
PHASE3
Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer
NCT02497157
COMPLETED
PHASE2
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer
NCT00416494
COMPLETED
PHASE2